The Latest Analyst Ratings for Taysha Gene Therapies
Portfolio Pulse from Benzinga Insights
Taysha Gene Therapies (NASDAQ:TSHA) has received positive analyst ratings in the last quarter, with 10 bullish and 3 somewhat bullish ratings. The average price target for the stock is $6.31, which is higher than its current price of $3.015, implying an upside. This average has increased by 5.17% from the previous average price target of $6.00.
September 20, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies has received positive analyst ratings, which could lead to an increase in its stock price.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Taysha Gene Therapies indicate that analysts are optimistic about the company's performance, which could attract more investors and lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100